Skip to main content

Table 2 Clinical studies to increase Treg frequency and function in different neurodegenerative disorders

From: Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders

Clinical Phase Intervention Condition Status Trial identifier Outcome
I & II Autologous Treg (GB301) AD Not yet recruiting NCT03865017
II Sargramostim (rhGM-CSF) AD Completed NCT01409915 Improved memory function [181]
Dimethyl fumarate (Tecfidera) MS Approved NCT02461069 Approved as first line monotherapy
Fingolimod (FTY720) MS Approved NCT00333138 First orally approved therapy
II Low dose IL-2 MS Recruiting NCT02424396
NA Vitamin D3 MS Completed NCT00940719 Unaffected Tregs [228]
II (WIRMS) Hookworm larvae MS Completed NCT01470521
I Sargramostim (rhGM-CSF) PD Completed NCT01882010 Improved motor function [24]
I Sargramostim (rhGM-CSF) PD Active NCT03790670
I Autologous Treg with IL-2 ALS Completed NCT03241784 Slow disease progression [225]
II Autologous Treg with IL-2 ALS Recruiting NCT04055623
II (MIROCALS) Riluzole with IL2 and 5% glucose water solution ALS Recruiting NCT03039673
II (TEALS) Dimethyl fumarate (Tecfidera) ALS Not yet recruiting ACTRN12618000534280